Q-omics provides the consensus-scored NSUN6 profile across patient tissues and cancer cell-line models. NSUN6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NSUN6 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, NSUN6 RNA expression shows 21,041 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where NSUN6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NSUN6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NSUN6 survival associations across molecular data types. NSUN6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NSUN6 RNA expression–survival associations across cancer types. High NSUN6 expression shows unfavorable associations in KIRC, COAD and ACC, but favorable associations in LUSC, LGG and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NSUN6 RNA expression.
This table summarizes NSUN6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NSUN6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NSUN6 shows lower tumor expression in THCA and higher tumor expression in STAD, COAD, LUAD, HNSC and KIRC. The THCA box plot shows higher NSUN6 RNA expression in normal versus tumor tissue (log2 FC = −0.641, t-test p < 0.001).
This table shows molecular features associated with NSUN6 in patient tissues and cancer cell lines. In patient samples, NSUN6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NSUN6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
